- Home
- CSTL vs THRY Comparison
CSTL vs THRY Comparison
Compare CSTL & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- THRY
- Stock Information
- Founded
- CSTL 2007
- THRY 2012
- Country
- CSTL United States
- THRY United States
- Employees
- CSTL N/A
- THRY N/A
- Industry
- CSTL Medical Specialities
- THRY Industrial Machinery/Components
- Sector
- CSTL Health Care
- THRY Industrials
- Exchange
- CSTL Nasdaq
- THRY Nasdaq
- Market Cap
- CSTL 561.9M
- THRY 594.8M
- IPO Year
- CSTL 2019
- THRY 2020
- Fundamental
- Price
- CSTL $16.53
- THRY $11.79
- Analyst Decision
- CSTL Strong Buy
- THRY Strong Buy
- Analyst Count
- CSTL 6
- THRY 5
- Target Price
- CSTL $37.67
- THRY $21.40
- AVG Volume (30 Days)
- CSTL 396.8K
- THRY 488.8K
- Earning Date
- CSTL 08-04-2025
- THRY 07-30-2025
- Dividend Yield
- CSTL N/A
- THRY N/A
- EPS Growth
- CSTL N/A
- THRY N/A
- EPS
- CSTL N/A
- THRY N/A
- Revenue
- CSTL $347,083,000.00
- THRY $771,903,000.00
- Revenue This Year
- CSTL N/A
- THRY N/A
- Revenue Next Year
- CSTL $1.36
- THRY N/A
- P/E Ratio
- CSTL N/A
- THRY N/A
- Revenue Growth
- CSTL 38.43
- THRY N/A
- 52 Week Low
- CSTL $15.45
- THRY $10.03
- 52 Week High
- CSTL $35.84
- THRY $20.92
- Technical
- Relative Strength Index (RSI)
- CSTL 34.83
- THRY 38.72
- Support Level
- CSTL $19.29
- THRY $11.81
- Resistance Level
- CSTL $20.26
- THRY $13.48
- Average True Range (ATR)
- CSTL 0.70
- THRY 0.50
- MACD
- CSTL -0.35
- THRY -0.06
- Stochastic Oscillator
- CSTL 4.44
- THRY 1.17
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About THRY Thryv Holdings Inc.
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. Its company is built upon a rich legacy in the marketing and advertising industry. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable SMB clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation, and run their day-to-day operations to save time, compete and win in today's SMB environment. The group has two business segments; Thryv SaaS and Thryv Marketing Services.